3SBio CEO Jing Lou On Building An Integrated Biopharma Company In China: An Interview With PharmAsia News
This article was originally published in PharmAsia News
Executive Summary
Shenyang Sunshine Pharmaceutical Company Limited, now known as 3SBio, was incorporated in 1993 in Shenyang, China, and was the first Chinese biotech company to list on NASDAQ. The company develops and manufactures recombinant protein-based products, including erythropoietin stimulating agents such as the firm's flagship product EPIAO. 3SBio CEO and co-founder Jing Lou spoke recently with PharmAsia News' Shanghai bureau about building an integrated biopharmaceutical company in China, and the opportunities and challenges of competing in the global market.
You may also be interested in...
After Brazil Onto China? Amgen Unveils Emerging Market Strategy
The world's largest biotech company Amgen Inc. aims to triple sales from emerging markets in five years through potential acquisitions and licensing back rights to current products, the company said during an April 21 business review meeting. Amgen's recent purchase of privately held Bergamo of Brazil for roughly $215 million, and its reacquisition of Brazilian rights to certain Amgen products from Mantecorp, indicate more such deals are on the way, analysts say
After Brazil Onto China? Amgen Unveils Emerging Market Strategy
The world's largest biotech company Amgen Inc. aims to triple sales from emerging markets in five years through potential acquisitions and licensing back rights to current products, the company said during an April 21 business review meeting. Amgen's recent purchase of privately held Bergamo of Brazil for roughly $215 million, and its reacquisition of Brazilian rights to certain Amgen products from Mantecorp, indicate more such deals are on the way, analysts say
New EPO Products Set To Boost Future Revenue For 3SBio
SHANGHAI - 3SBio generated revenues from increased sales of its recombinant human erythropoietin products but saw its earnings slip, according to the unaudited financial results for the second quarter ended June 30